Equity Profile

CVS

CVS Health Corporation

Health CareHealth Care Services$116.1B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CVS Health Corporation is a major player in the health care sector, providing a range of services including pharmacy benefits, retail pharmacy, and health insurance. With a market cap of $116 billion, CVS is positioned at the intersection of health care and consumer services, making it a significant contributor to the evolving health care landscape.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $2.57.

Revenue Growth

Revenue growth reflects the company's ability to expand its business and capture market share, which is crucial for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+17.38%

Avg Stock Reaction

+4.06%

Last Quarter Recap

In Q1-2026, CVS reported an EPS of $2.57, exceeding expectations by 16.39%. The stock reacted positively, gaining 7.65% the following day.

Management Promises & Guidance

Continue to focus on expanding pharmacy services.
Enhance integration of health care offerings.
Commit to improving customer experience across all platforms.

Expectations

Wall Street Expectations

Overall, investors are optimistic about CVS's ability to maintain its growth trajectory, especially following strong earnings in the previous quarter.

Bull Case

If CVS can deliver strong EPS and show robust revenue growth, it could reinforce investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, any signs of slowing growth or disappointing revenue could raise concerns about the company's long-term prospects, leading to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.57.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its business and capture market share, which is crucial for long-term success.

Pharmacy Benefit Management (PBM) Revenue

Not available.

As a significant part of CVS's business, PBM revenue indicates how well the company is managing its pharmacy services and contracts.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to last quarter's $2.57?

A strong EPS could indicate continued profitability, while a decline might raise concerns about CVS's growth.

How is CVS performing in its Pharmacy Benefit Management segment?

Given the importance of this segment to CVS's overall business, insights here could significantly impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CVS's ability to leverage its integrated health services to drive revenue growth, especially in the PBM segment.

Supporting Evidence

CVS has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in health care spending could favor CVS's diversified offerings.

Key Risk

If PBM revenue shows unexpected growth, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect CVS's ability to sustain its growth momentum amidst a competitive health care landscape.

Bull Confirmed If

An EPS of $2.70 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $2.50 would confirm the bear case, suggesting potential issues with growth.

Pre-Earnings Positioning

Options Market

Implied Move

±7.03%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±7.0% while CVS has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.7%

Calls (563K)P/C Ratio: 0.42Puts (383K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CVS beats expectations, history suggests the stock could rise by around 4.06%, confirming strong operational performance.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess growth prospects.

Miss

In the event of a miss, history suggests a potential decline of around 5.45%, reflecting disappointment in performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

Senate only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-ARJohn BoozmanSen.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the performance of the Pharmacy Benefit Management segment.
2Any updates on new health care initiatives or partnerships.
3Insights into customer retention and acquisition strategies.
4Management's outlook on future revenue growth.
5Responses to competitive pressures in the health care market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $2.57.

Revenue Growth

Revenue growth reflects the company's ability to expand its business and capture market share, which is crucial for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+17.38%

Avg Stock Reaction

+4.06%

Last Quarter Recap

In Q1-2026, CVS reported an EPS of $2.57, exceeding expectations by 16.39%. The stock reacted positively, gaining 7.65% the following day.

Management Promises & Guidance

Continue to focus on expanding pharmacy services.
Enhance integration of health care offerings.
Commit to improving customer experience across all platforms.

Expectations

Wall Street Expectations

Overall, investors are optimistic about CVS's ability to maintain its growth trajectory, especially following strong earnings in the previous quarter.

Bull Case

If CVS can deliver strong EPS and show robust revenue growth, it could reinforce investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, any signs of slowing growth or disappointing revenue could raise concerns about the company's long-term prospects, leading to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.57.

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its business and capture market share, which is crucial for long-term success.

Pharmacy Benefit Management (PBM) Revenue

Not available.

As a significant part of CVS's business, PBM revenue indicates how well the company is managing its pharmacy services and contracts.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to last quarter's $2.57?

A strong EPS could indicate continued profitability, while a decline might raise concerns about CVS's growth.

How is CVS performing in its Pharmacy Benefit Management segment?

Given the importance of this segment to CVS's overall business, insights here could significantly impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CVS's ability to leverage its integrated health services to drive revenue growth, especially in the PBM segment.

Supporting Evidence

CVS has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in health care spending could favor CVS's diversified offerings.

Key Risk

If PBM revenue shows unexpected growth, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect CVS's ability to sustain its growth momentum amidst a competitive health care landscape.

Bull Confirmed If

An EPS of $2.70 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $2.50 would confirm the bear case, suggesting potential issues with growth.

Pre-Earnings Positioning

Options Market

Implied Move

±7.03%

Historical Avg

±5.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±7.0% while CVS has averaged ±5.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.7%

Calls (563K)P/C Ratio: 0.42Puts (383K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CVS beats expectations, history suggests the stock could rise by around 4.06%, confirming strong operational performance.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess growth prospects.

Miss

In the event of a miss, history suggests a potential decline of around 5.45%, reflecting disappointment in performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

Senate only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-ARJohn BoozmanSen.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the performance of the Pharmacy Benefit Management segment.
2Any updates on new health care initiatives or partnerships.
3Insights into customer retention and acquisition strategies.
4Management's outlook on future revenue growth.
5Responses to competitive pressures in the health care market.